SCHEDULE: Aptose Biosciences: Bleichroeder Discloses 1.61% Stake

Bleichroeder LP and affiliates report a passive 1.61% beneficial ownership in Aptose Biosciences Inc. common shares.

Summary

• Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach collectively reported beneficial ownership of 41,666 common shares of Aptose Biosciences Inc.
• This ownership represents 1.61% of the common shares outstanding.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating an update to a previously filed statement.
• Bleichroeder LP is classified as an Investment Adviser (IA), while Bleichroeder Holdings LLC and Andrew Gundlach are classified as Parent Holding Company/Control Person (HC).
• The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Filing is a routine disclosure of passive beneficial ownership, indicating no significant positive or negative operational or financial news.

Positives

• The filing indicates continued investment by Bleichroeder LP and its affiliates in Aptose Biosciences Inc.

Risks

• The filing itself does not detail company-specific operational or financial risks, focusing solely on beneficial ownership disclosure.

Stakeholder Impact

• Minimal impact on shareholders as it's a passive ownership disclosure below the 5% threshold, indicating no intent to influence control.

Key Dates

Keywords

Aptose Biosciences, Bleichroeder, Schedule 13G, Beneficial Ownership, Common Shares, Investment Adviser, Biotechnology, SEC Filing